{
    "root": "f7334753-35b3-450f-b6f6-2bf22d54a30f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Brevibloc",
    "value": "20250314",
    "ingredients": [
        {
            "name": "ESMOLOL HYDROCHLORIDE",
            "code": "V05260LC8D",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4857"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32954"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        }
    ],
    "indications": {
        "text": "brevibloc injection beta adrenergic blocker indicated short-term treatment : \u2022 control ventricular rate supraventricular tachycardia including atrial fibrillation atrial flutter control heart rate noncompensatory sinus tachycardia ( 1.1 ) \u2022 control perioperative tachycardia hypertension ( 1.2 )",
        "doid_entities": [
            {
                "text": "atrial fibrillation (DOID:0060224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0060224"
            },
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 administer intravenously ( 2.1 , 2.2 ) \u2022 titrate using ventricular rate blood pressure \u22654-minute intervals . ( 2.1 , 2.2 ) \u2022 supraventricular tachycardia ( svt ) noncompensatory sinus tachycardia ( 2.1 ) \u2022 optional loading dose : 500 mcg per kg infused one minute \u2022 50 mcg per kg per minute next 4 minutes \u2022 adjust dose needed maximum 200 mcg per kg per minute . \u2022 additional loading doses may administered \u2022 perioperative tachycardia hypertension ( 2.2 ) \u2022 loading dose : 500 mcg per kg 1 minute gradual control ( 1 mg per kg 30 seconds immediate control ) \u2022 50 mcg per kg per min gradual control ( 150 mcg per kg per minute immediate control ) adjusted maximum 200 ( tachycardia ) 300 ( hypertension ) mcg per kg per min ( 2.2 )",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "brevibloc ( esmolol hydrochloride ) injection contraindicated patients : \u2022severe sinus bradycardia : may precipitate worsen bradycardia resulting cardiogenic shock cardiac arrest [ ( 5.2 ) ] . \u2022heart block greater first degree : second- third-degree atrioventricular block may precipitate worsen bradycardia resulting cardiogenic shock cardiac arrest [ ( 5.2 ) ] . \u2022sick sinus syndrome : may precipitate worsen bradycardia resulting cardiogenic shock cardiac arrest [ ( 5.2 ) ] . \u2022decompensated heart failure : may worsen heart failure . \u2022cardiogenic shock : may precipitate cardiovascular collapse cause cardiac arrest . \u2022iv cardiodepressant calcium-channel antagonists ( e.g . , verapamil ) brevibloc injection close proximity ( i.e . , cardiac effects still present ) ; fatal cardiac arrests occurred patients receiving brevibloc injection intravenous verapamil . \u2022pulmonary hypertension : may precipitate cardiorespiratory compromise . \u2022hypersensitivity , including anaphylaxis , esmolol inactive ingredients product ( cross-sensitivity beta blockers possible ) .",
    "indications_original": "BREVIBLOC injection is a beta adrenergic blocker indicated for the short-term treatment of: \u2022 Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia  ( 1.1 ) \u2022 Control of perioperative tachycardia and hypertension  ( 1.2 )",
    "contraindications_original": "\u2022 Administer intravenously  ( 2.1 , 2.2 ) \u2022 Titrate using ventricular rate or blood pressure at \u22654-minute intervals.  ( 2.1 , 2.2 ) \u2022 Supraventricular tachycardia (SVT) or noncompensatory sinus tachycardia  ( 2.1 ) \u2022 Optional loading dose: 500 mcg per kg infused over one minute \u2022 Then 50 mcg per kg per minute for the next 4 minutes \u2022 Adjust dose as needed to a maximum of 200 mcg per kg per minute. \u2022 Additional loading doses may be administered \u2022 Perioperative tachycardia and hypertension  ( 2.2 ) \u2022 Loading dose: 500 mcg per kg over 1 minute for gradual control (1 mg per kg over 30 seconds for immediate control) \u2022 Then 50 mcg per kg per min for gradual control (150 mcg per kg per minute for immediate control) adjusted to a maximum of 200 (tachycardia) or 300 (hypertension) mcg per kg per min  ( 2.2 )",
    "adverseReactions_original": "BREVIBLOC (Esmolol Hydrochloride) injection is contraindicated in patients with:\n                  \n                     \n                        \u2022Severe sinus bradycardia:  May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].\n                     \n                     \n                        \u2022Heart block greater than first degree:  Second- or third-degree atrioventricular block may precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].\n                     \n                     \n                        \u2022Sick sinus syndrome:  May precipitate or worsen bradycardia resulting in cardiogenic shock and cardiac arrest [see Warnings and Precautions (5.2)].\n                     \n                     \n                        \u2022Decompensated heart failure:  May worsen heart failure.\n                     \n                        \u2022Cardiogenic shock:  May precipitate further cardiovascular collapse and cause cardiac arrest.\n                     \n                        \u2022IV administration of cardiodepressant calcium-channel antagonists (e.g., verapamil) and BREVIBLOC injection in close proximity (i.e., while cardiac effects from the other are still present); fatal cardiac arrests have occurred in patients receiving BREVIBLOC injection and intravenous verapamil.\n                     \n                        \u2022Pulmonary hypertension:  May precipitate cardiorespiratory compromise.\n                     \n                        \u2022Hypersensitivity reactions, including anaphylaxis, to esmolol or any of the inactive ingredients of the product (cross-sensitivity between beta blockers is possible).",
    "drug": [
        {
            "name": "Brevibloc",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_4857"
        }
    ]
}